Quick Takeaways:
- Genflow Biosciences Plc expanded its engagement with Tier-1 global animal health companies following positive preliminary interim data from its canine SIRT6 cent gene therapy programme reported in February 2026.
- The company has signed additional confidentiality agreements with global animal health players to support ongoing evaluations of data and underlying technology related to its canine longevity-focused gene therapy platform.
- Genflow said the discussions remain exploratory, with CEO Dr. Eric Leire noting that a broader group of counterparties is now reviewing the programme as the company continues generating further development data.
Why It Matters?
Genflow’s early canine SIRT6 data are strong enough that big animal‑health players now want a closer look, but not yet strong enough for anyone to sign a deal.
The expanded web of NDAs suggests real strategic interest in longevity‑focused pet gene therapy and sets Genflow up for potential licensing or co‑development talks once it can show more mature, durable outcomes from the dog study.
Source: Genflow
